Bruker Co. (BRKR) to Issue Quarterly Dividend of $0.05 on March 28th

Bruker Co. (NASDAQ:BRKR) announced a quarterly dividend on Tuesday, February 18th, Wall Street Journal reports. Stockholders of record on Monday, March 17th will be paid a dividend of 0.05 per share by the medical research company on Friday, March 28th. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.44%. The ex-dividend date of this dividend is Monday, March 17th.

Bruker has raised its dividend by an average of 7.7% per year over the last three years. Bruker has a payout ratio of 6.5% indicating that its dividend is sufficiently covered by earnings. Equities analysts expect Bruker to earn $3.15 per share next year, which means the company should continue to be able to cover its $0.20 annual dividend with an expected future payout ratio of 6.3%.

Bruker Trading Up 2.2 %

NASDAQ:BRKR opened at $45.97 on Friday. Bruker has a 12-month low of $44.11 and a 12-month high of $94.86. The firm has a market capitalization of $6.97 billion, a P/E ratio of 60.49, a P/E/G ratio of 2.16 and a beta of 1.18. The company has a debt-to-equity ratio of 1.15, a current ratio of 1.60 and a quick ratio of 0.77. The business has a 50 day simple moving average of $53.93 and a 200 day simple moving average of $58.57.

Bruker (NASDAQ:BRKR) last released its quarterly earnings data on Thursday, February 13th. The medical research company reported $0.76 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.75 by $0.01. Bruker had a return on equity of 21.01% and a net margin of 3.36%. Equities research analysts predict that Bruker will post 2.69 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. Barclays reduced their price objective on Bruker from $69.00 to $65.00 and set an “overweight” rating for the company in a research report on Monday, February 10th. Bank of America boosted their price target on Bruker from $78.00 to $80.00 and gave the stock a “buy” rating in a research report on Friday, December 13th. UBS Group started coverage on Bruker in a research report on Tuesday, December 10th. They set a “neutral” rating and a $66.00 price target for the company. The Goldman Sachs Group upgraded Bruker from a “sell” rating to a “neutral” rating and set a $60.00 price target for the company in a research report on Thursday, December 5th. Finally, Guggenheim reiterated a “buy” rating on shares of Bruker in a research report on Monday, February 24th. Six analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $70.50.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.